NDA 019853 · Valeant Pharms Intl
Cuprimine
Penicillamine · Oral · Antirheumatic Agent
NovelLast checked: Nov 20, 2026Latest source record: Oct 26, 2004 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1970
Dec 4, 1970
Approved uses
1
Original approval plus efficacy supplements
Registered trials
12
6 Phase 3, 1 recruiting
FAERS reports
914
706 serious, 91 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
Physicians planning to use penicillamine should thoroughly familiarize themselves with its toxicity, special dosage considerations, and therapeutic benefits. Penicillamine should never be used casually. Each patient should remain constantly under the close supervision of the physician. Patients should be warned to report promptly any symptoms suggesting toxicity.
What it is approved for
From the label in effect Jan 26, 2026.
INDICATIONS CUPRIMINE is indicated in the treatment of Wilson’s disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that CUPRIMINE is not of value in ankylosing spondylitis. Wilson’s Disease Wilson’s disease (hepatolenticular degeneration) occurs in individuals who have inherited an autosomal-recessive defect that leads to an accumulation of copper far in excess of metabolic requirements. The excess copper is deposited in several organs and tissues, and eventually produces pathological effects primarily in the liver, where damage progresses to postnecrotic cirrhosis, and in the brain, where degeneration is widespread. Copper is also deposited as characteristic, asymptomatic, golden-brown Kayser-Fleischer rings in the corneas of all patients with cerebral symptomatology and some patients who are either asymptomatic or manifest only hepatic symptomatology. Two types of patients require treatment for Wilson’s disease: (1) the symptomatic, and (2) the asymptomatic in whom it can be assumed the disease will develop in the future if the patient is not treated. The diagnosis, if suspected on the basis of family or individual history or physical examination, can be confirmed if the plasma copper-protein ceruloplasmin** is less than 20 mg/dL and either a quantitative determination in a liver biopsy specimen shows an abnormally high concentration of copper (greater than 250 mcg/g dry weight) or Kayser-Fleischer rings are present. Treatment has two objectives: (1) to minimize dietary intake of copper; (2) to promote excretion and complex formation (i.e., detoxification) of excess tissue copper. The first objective is attained by a daily diet that contains...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 4, 1970 Original approval · Type 1 - New Molecular Entity
2 products under this application
- CUPRIMINE · PENICILLAMINE 125MG · CAPSULE, ORAL · Discontinued
- CUPRIMINE · PENICILLAMINE 250MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Penicillamine" as an intervention, any sponsor and status, largest first.
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT03957720 · 400 participants (planned) · Start Mar 15, 2019 · Primary completion Dec 31, 2024
Drug: DMPS; Penicillamine and 2 more · For: Wilson's Disease
Sites: Hangzhou, China
- A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)Pivotal-lookingCompleted
Astellas Pharma China, Inc.Astellas (ALPMY)
NCT03660059 · 385 participants · Start Sep 27, 2018 · Primary completion Apr 1, 2021
Drug: Peficitinib; Plaebo and 1 more · For: Rheumatoid Arthritis (RA)
Sites: Anhui, China; Beijing, China; Bengbu, China · 43 sites in all
- Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson DiseasePivotal-lookingTerminated
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT03403205 · 214 participants · Start Feb 22, 2018 · Primary completion Jun 30, 2023
Drug: ALXN1840; SoC Therapy · For: Wilson Disease
Sites: Los Angeles, California; New Haven, Connecticut; Chicago, Illinois · 56 sites in all
- Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-PenicillamineStatus unknown
Univar BVIndustry
NCT02426905 · 90 participants (planned) · Start Jan 2016 · Primary completion May 2018
Drug: trientine dihydrochloride · For: Wilson Disease
Sites: Heidelberg, Germany; Goudi, Greece; Milan, Italy · 4 sites in all
- Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's DiseasePivotal-lookingCompleted
OrphalanIndustry
NCT03539952 · 77 participants · Start Sep 3, 2018 · Primary completion Aug 19, 2020
Drug: Penicillamine (D1-W12); TETA 4HCL (W12-60) and 2 more · For: Wilson Disease
Sites: New Haven, Connecticut; Leuven, Belgium; Curitiba, Brazil · 15 sites in all
- Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With GlioblastomaCompleted
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
NCT00003751 · 40 participants (planned) · Start Mar 1999 · Primary completion Jun 2004
Drug: penicillamine · For: Brain and Central Nervous System Tumors
Sites: Birmingham, Alabama; Tampa, Florida; Atlanta, Georgia · 9 sites in all
- Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson DiseasePivotal-lookingTerminated
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT05047523 · 40 participants · Start Sep 13, 2021 · Primary completion Jun 26, 2023
Drug: ALXN1840; Standard of Care · For: Wilson Disease
Sites: Parkville, Australia; South Brisbane, Australia; Lille, France · 20 sites in all
- Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.Pivotal-lookingRecruiting
OrphalanIndustry
NCT07465718 · 38 participants (planned) · Start Sep 3, 2026 · Primary completion Feb 2028
Drug: TETA 4HCl formulation; D-Penicillamine · For: Wilson's Disease
Sites: Denver, Colorado; New Haven, Connecticut; Ann Arbor, Michigan · 10 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug hypersensitivity181
- drug ineffective175
- arthralgia148
- joint swelling143
- inflammation111
- nausea94
- off label use94
- diarrhoea89
- headache83
- hypersensitivity81
- drug intolerance79
- anaphylactic reaction77
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 47 |
| 2005 | 31 |
| 2006 | 21 |
| 2007 | 22 |
| 2008 | 16 |
| 2009 | 25 |
| 2010 | 23 |
| 2011 | 25 |
| 2012 | 14 |
| 2013 | 15 |
| 2014 | 16 |
| 2015 | 17 |
| 2016 | 39 |
| 2017 | 77 |
| 2018 | 82 |
| 2019 | 90 |
| 2020 | 117 |
| 2021 | 68 |
| 2022 | 48 |
| 2023 | 42 |
| 2024 | 29 |
| 2025 | 36 |
| 2026 | 14 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cuprimine (Penicillamine)
2024 spending
$1.9M
Beneficiaries
n/a
57 claims
Per beneficiary
n/a
$252.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,088,859 |
| 2021 | $3,404,409 |
| 2022 | $2,531,210 |
| 2023 | $2,095,299 |
| 2024 | $1,944,581 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cystinuria: clinical practice recommendation.
Servais A, Thomas K, Dello Strologo L, et al. · Kidney Int 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Rheumatoid arthritis.
Walker-Bone K, Farrow S · BMJ Clin Evid 2007 · Systematic Review
- Penicillamine for treating rheumatoid arthritis.
Suarez-Almazor ME, Spooner C, Belseck E · Cochrane Database Syst Rev 2000 · Systematic Review
- D-penicillamine for primary sclerosing cholangitis.
Klingenberg SL, Chen W · Cochrane Database Syst Rev 2006 · Systematic Review
- Methotrexate for treating rheumatoid arthritis.
Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial.
Schilsky ML, Czlonkowska A, Zuin M, et al. · Lancet Gastroenterol Hepatol 2022 · Clinical Trial, Phase III, Equivalence Trial
Sponsor: Valeant Pharms Intl
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.